Status of Dyslipidemia Management with Statins, in In-patients with known Coronary Artery Disease confirmed by angiographic findings
Aim: To determine the status of dyslipidemia management with statins in In-patients with known Coronary Artery Disease (CAD) confirmed by angiographic findings.
Methods: This study has been conducted in a corporate cardiac centre at Visakhapatnam, Andhra Pradesh. This study is a retrospective analysis of data collected from the electronic medical records in terms of age, sex, CAD status, associated risk factors, statin usage, and lipid parameters.
Results: Among a sample of 92 known CAD in-patients, 81.5% achieved LDL-C goal of <100 mg/dl as recommended by Third Report of the National Cholesterol Education Program (NCEP) Adult Treatment Panel III [ATP III] for CAD and CAD risk equivalents. Success rates among males and females are 79.7% and 85% respectively. 78.2% of 69 patients on Atorvastatin, 85% of 20 patients on Rosuvastatin and 100% of 3 patients on Simvastatin achieved LDL-C goal. If the target LDL-C level is kept at <70 mg/dl as defined as optional goal for very high risk CAD and CAD risk equivalents, the success rate is only 31.5%.
Conclusion: The Success rates for achieving LDL-C goals (<100mg/dl) is satisfactory in this facility. But the major concern in this study is even with desired LDL-C levels 61% of these in-patients suffered with a recurrent CAD leaving an opportunity to reconsider the target LDL-C to still lower levels (<70 mg/dl) which is mentioned just as an optional for very high risk candidates in NCEP ATP-III guidelines.
. Gupta R. Recent trends in coronary heart disease epidemiology in India. Indian Heart J 2008 March;60(2 Suppl B): B4-18.
. Anand SS, Islam S, Rosengren A et al. Risk factors for myocardial infarction in women and men: insights from the Interheart study. Eur Heart J 2008 April; 29(7): 932-40.
. McConnell KJ, Olson KL, Delate T, Merenich JA. Factors associated with recurrent coronary events among patients with cardiovascular disease. Pharmacotherapy 2009 August; 29(8):906-13.
. Pfefferkorn JA. Novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: a patent review. Expert Opin Ther Pat 2011 February;21(2):187-203.
. Aarabi M, Jackson PR. Prevention of coronary heart disease with statins in UK South Asians and Caucasians. Eur J Cardiovasc Prev Rehabil 2007 April;14(2):333-9.
. Arca M, Gaspardone A. Atorvastatin efficacy in the primary
and secondary prevention of cardiovascular events. Drugs 2007; 67 Suppl 1: 29-42.
. Girman CJ, Rhodes T, Mercuri M et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004 January 15;93(2):136-41.
. Shiffman D, Sabatine MS, Louie JZ et al. Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial. Am J Cardiol 2010 May 1;105(9):1300-5.
. Pedersen TR, Olsson AG, Faergeman O et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). 1998. Atheroscler Suppl 2004 October; 5(3): 99-106.
. Pedersen TR. Coronary artery disease: the Scandinavian Simvastatin Survival Study experience. Am J Cardiol 1998 November 26;82(10B):53T-6T.
. Homma Y. [LIPID study [Long-term Intervention with Pravastatin in Ischaemic Disease study]]. Nihon Rinsho 2001 March;59 Suppl 3:416-21.
. Tonkin AM. Management of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995 September 28;76(9):107C-12C.
. Arrospide A, Mar J, Vivancos-Mora J, Rejas-Gutierrez J, Caro J. [Cost-effectiveness analysis of using high doses of atorvastatin for the secondary stroke prevention in Spain]. Rev Neurol 2010 July 1;51(1):1-11.
. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 December 17;106(25):3143-421.
. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000 February 28;160(4): 459-67.
. Waters DD, Brotons C, Chiang CW et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009 July 7;120(1): 28-34.
. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003 June 14; 361(9374): 2005-16.
. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002 November 23; 360(9346):1623-30.
. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002 December 18;288(23):2998-3007.
. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 April 5;361(9364):1149-58.
. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010 November 13;376(9753):1670-81.
. Muniz J, Gomez-Doblas JJ, Santiago-Perez MI et al. The effect of post-discharge educational intervention on patients in achieving objectives in modifiable risk factors six months after discharge following an episode of acute coronary syndrome, (CAM-2 Project): a randomized controlled trial. Health Qual Life Outcomes 2010;8:137.
. Maron DJ, Boden WE, O'Rourke RA et al. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol 2010 March 30;55(13):1348-58.
Copyright (c) 2017 International Journal of Biomedical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- An author must submit Copyright form After acceptance of the article.